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MASSIVE APOPTOSIS OF BONE MARROW CELLS IN APLASTIC ANAEMIA
The pathogenesis of aplastic anaemia (AA) is still incom-
pletely understood. Bone marrow (BM) hypoplasia is a
hallmark of AA and one of the considered mechanisms of
hypoplasia is an increased apoptosis of haematopoietic
progenitors. However, definitive evidence supporting this is
largely lacking (Ismail et al, 2001).
We have studied in situ apoptosis of BM mononuclear
cells (BMMNCs) in the BM biopsies of 10 AA patients. All
the patients had acquired AA and none of the patients
had received prior immunosuppressive treatment. Two
patients had very severe AA (VSAA), five had severe AA
(SAA) and three had non-severe AA (NSAA) (Camitta
et al, 1979; Bacigalupo et al, 1988). Ten age- ⁄ sex-
matched lymphoma patients with no infiltration of BM
by lymphomatous cells, as confirmed by microscopy and
immunophenotyping, served as controls. Apoptosis was
detected by TdT-mediated dUTP nick end labelling
(TUNEL) assay using the in situ cell death detection kit-
Fluorescein (Boehringer Mannheim, Germany). The fluor-
escent signal was converted into light microscopy by
treating the sections with antifluorescein-alkaline phos-
phatase (Boehringer) and its substrate, fast red (Sigma, St
Louis, MO, USA). Mayer’s Haematoxylin was used as
counter-stain. The number of apoptotic BMMNCs were
54Æ14 ± 13Æ22% in the biopsies of patients (Fig 1A) and
3Æ78 ± 1Æ85% in those of controls (Fig 1B) (P < 0Æ001).
The apoptotic index observed in patients with VSAA and
SAA was significantly higher than in those with NSAA
(61Æ0 ± 10% versus 39Æ0 ± 4%, P < 0Æ05), suggesting a
correlation between severity of the disease and degree of
apoptosis.
In a previous study, Callera & Falcao (1997), using the
same method, reported significantly increased apoptosis in
the biopsies of AA patients compared with controls.
However, the apoptotic index observed by this group
(8Æ19 ± 1Æ45%) was much lower than ours (54Æ14 ±
13Æ22%). This may be due to differences in the clinical
spectrum of patients and the protocol of the method used.
All the patients included in our study were untreated and
most of them (7 ⁄10) had SAA ⁄VSAA. However, most of
the patients (6 ⁄11) of Callera & Falcao (1997) had been
previously treated and had moderate disease (7 ⁄11). Use of
suboptimal concentration of Proteinase K (Sigma) or
treatment time of tissue sections with the enzyme can
give false results. We determined the optimal concentra-
tion as well as treatment time of Proteinase K (20 lg ⁄ml
for 30 min) by studying apoptosis in control biopsies
treated with graded concentrations of DNase I (Sigma).
However, the concentration and time period of incubation
with Proteinase K was not clear in the report of Callera &
Falcao (1997).
The massive BMMNC apoptosis that we observed was in
accordance with a previous report showing a significant
increase in haematopoietic cells bearing Fas antigen
(56 ± 9%) (Maciejewski et al, 1995). Furthermore, our
data corroborates with two recent reports showing signifi-
cant apoptosis ⁄ death of CD34+ cells in BM of AA patients
(Killick et al, 2000; Ismail et al, 2001).
In conclusion, we have observed massive apoptosis of
BMMNCs in our patients, suggesting that apoptotic death of
marrow cells may be a major cause of BM hypoplasia in AA.
Further studies on phenotypic characterization of apoptotic
Fig 1. (A) Representative photomicrograph showing TUNEL staining of BM biopsy of an AA patient (·100). The pink nuclei represent the
apoptotic cells and purple nuclei represent non-apoptotic cells. (B) Representative photomicrograph showing TUNEL staining of BM biopsy of a
control (·100). The purple nuclei represent non-apoptotic cells.
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marrow cells and precise mechanism(s) of their apoptosis
will provide important new insights in understanding the
pathophysiology of the disease.
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POST-TRANSFUSION PURPURA WITHOUT DETECTABLE ANTIBODIES: THEIR ADSORPTION
FROM THE PLASMA BY MULTIPLE INCOMPATIBLE PLATELET TRANSFUSIONS
About 200 cases of post-transfusion purpura (PTP) have
been reported (Mueller-Eckhardt, 1986; Kunicki & Beards-
ley, 1989; Taaning & Svejgaard, 1994). This syndrome
occurs most frequently in women, presumably due to
immunization during previous pregnancies (Mueller-
Eckhardt, 1986). The target antigen in most cases is
human platelet antigen 1a (HPA-1a). PTP may occur more
frequently than has been recognized, as its clinical
diagnosis is based on a sudden drop of platelets after
transfusion, which does not occur in pre-existing throm-
bocytopenia. We describe a female patient who had
preformed HPA-1a antibodies which were not detectable
at the time of severe thrombocytopenia, presumably due to
their adsorption by continuously administered platelet
concentrates.
A 49-year-old mother of two children with liver cirrhosis
was scheduled for liver transplantation. HPA-1a antibodies
had been detected 2 years earlier. In the preceding year
she had received 14 units of filtered packed red blood cells
(PRBC), which were unmatched for the HPA system,
during surgery for a duodenal ulcer. No platelet concen-
trates (PC) were transfused. On the day of the liver
transplantation, her haemoglobin was 11Æ2 g ⁄ dl and the
platelet count was 40 · 109 ⁄ l. The report on the platelet
antibodies had not been forwarded from the laboratory.
The patient received 8 units of filtered PRBC, 6 units of
frozen plasma and one leucocyte-filtered PC intraopera-
tively. The platelet count dropped to < 10 · 109 ⁄ l (Fig 1).
There was no increase of platelet counts despite daily
transfusions with unselected single donor apheresis PC,
retrospectively typed as HPA-1a. An antibody screening by
the monoclonal antibody-specific immobilization of platelet
antigens (MAIPA) assay (Kurz et al, 2001) on sera taken
on two different days revealed human leucocyte antigen
(HLA) antibodies and a positive cross-match with the first
PC due to these antibodies, but no other platelet antibodies.
However, the patient was genotyped HPA-1bb, 2aa, 3aa,
5aa and a diagnosis of PTP was presumed. All transfusions
were stopped. She received intravenous immunoglobulin
Fig 1. The course of HPA-1a antibodies (n) and peripheral
platelet counts (d) are shown. An optical density at 492 nm, after
subtraction of blanks (n OD), of more than 100 (—) by the
MAIPA assay was defined as a positive result. A total of six
platelet concentrates (r) were transfused. One was given during
surgery and five others within the first 3 d. … indicates the day of
surgery, and . indicates the days of i.v.Ig treatment (1 g ⁄ kg body
weight).
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(i.v.Ig) for three consecutive days and platelet counts rose
rapidly (Fig 1). Eight further PRBC from HPA-1bb donors
were well tolerated. A repeat evaluation of all sera within the
same MAIPA assay confirmed the presence of HPA-1a
antibodies, but only in sera obtained before surgery and after
recovery (Fig 1). The patient was discharged from hospital
3 weeks later with a platelet count of 262 · 109 ⁄ l.
Complex clinical situations with thrombocytopenia, such
as in patients undergoing chemotherapy, or in patients with
septicaemia or liver cirrhosis (Stiegler et al, 1998), may
mask PTP, which typically is indicated by a sudden drop of
platelet counts. Failure of platelet transfusions to increase
the platelet count may be interpreted as refractoriness to
platelet concentrates, but not as PTP. In this case we
assumed that intensive transfusions of incompatible platelets
adsorbed the antibodies from the plasma (Nagasawa et al,
1978), resulting in a negative test result. A diagnosis of PTP
was considered, however, because the patient was geno-
typed HPA-1bb and therefore regarded at high risk for PTP.
It is assumed that PTP is due to boosting of alloantibodies,
resulting in a premature clearance of the transfused and
autologous platelets. In this case we cannot document
boosting of the antibodies. In contrast, we showed the
presence of the antibodies prior to transfusion. Whether or
not the boosting of antibodies is a prerequisite for PTP is not
known, as the absence of antibodies prior to transfusions
has only been documented in a few case of PTP (Mueller-
Eckhardt, 1986). However, the drop of platelets after
transfusion of the first PC below pretransfusion levels and
the rapid response to i.v.Ig support the assumption of PTP.
Thus, this case illustrates that PTP may not be recognized if
the diagnosis is based on the detection of platelet antibodies,
which can be adsorbed from the plasma by transfused
platelets.
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HEPATOSPLENIC cd T-CELL LYMPHOMA: COMPLETE RESPONSE INDUCED BY TREATMENT
WITH PENTOSTATIN
Hepatosplenic cd T-cell lymphoma (HScdTCL) is a rare but
distinct entity (Farcet et al, 1990), which mainly affects
young males and is characterized by hepatosplenomegaly
but no or little lymphoadenopathy, frequent B symptoms,
thrombocytopenia and poor response to conventional
chemotherapy (Wong et al, 1995). A wide and heteroge-
neous array of therapies has been applied: monotherapy
with steroids or alkylating agent, fludarabine, splenectomy,
polychemotherapy and bone marrow transplantation.
Despite different therapeutic approaches, complete remis-
sion (CR) is rarely obtained and the few responding
patients relapse early with virtually all patients dying
within 2 years (Weidmann, 2000). Pentostatine is a
potent inhibitor of adenosine deaminase with a marked
cytotoxic activity on T lymphocytes and has been shown
to be effective in treatment of some histotypes of T-cell
lymphomas (Kurzrock, 2000). Recent evidence displayed
sensitivity of cd cells to pentostatine in vitro (Aldinucci
et al, 2000) and prompted us to treat a patient affected
with HScdTSL using this drug.
In April 1999, a 42-year-old Caucasian man was
admitted to our ward because of night sweats, weight loss,
dull pain at left ipocondrium, mild anaemia and thrombo-
cytopenia discovered 2 weeks previously. Physical exam-
ination highlighted massive splenomegaly (20 cm below left
costal margin) and hepatomegaly (7 cm below costal
margin at midclavicular line). Haematological and bio-
chemical tests revealed mild normochromic anaemia (Hb
10 g ⁄ dl) and thrombocytopenia (60 · 109 ⁄ l), severe neu-
tropenia and lymphocytopenia (white blood cells, 1Æ1 ·
109 ⁄ l; neutrophils, 0Æ4 · 109 ⁄ l; lymphocytes, 0Æ6 · 109 ⁄ l).
Lactate dehydrogenase and beta2 microglobulin were
within normal range. Virological tests documented an
acquired immunity for hepatitis B virus and Epstein–Barr
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virus, and were negative for hepatitis C virus and human
immunodeficiency virus infection. Bone marrow aspiration
showed a 40% infiltrate consisting of medium-sized lympho-
cytes with slightly indented nuclei, small nucleolus and a
small rim of lightly basophilic cytoplasm; the immunophe-
notype was as follows: CD3+, CD2+, CD8+, CD4–, CD5–,
CD10–, CD56 ⁄16+, TCR ab, TCR cd1+.
A bone marrow trephine biopsy demonstrated a charac-
teristic exclusively intrasinusoidal infiltrate consisting of
medium-sized T lymphocytes (immunohistochemistry ABC
Strept LCA+, CD20–, CD45RO+, CD45RA–).
The diagnosis of HScdTSL was made and the patient was
treated with pentostatin (4 mg ⁄m2 intravenously every
2 weeks for 6 months). The disappearance of B symptoms
and shrinkage of the spleen rapidly followed the first
administration of pentostatin. At restaging, performed after
10 courses of pentostatin, the patient was found to be in
complete remission (neither lymph nodes nor liver or spleen
enlargement were detected using a computerized tomogra-
phy scan and the bone marrow infiltrate was completely
clear). There was no significant treatment-related toxicity.
The patient received another two monthly courses of
pentostatin and subsequently underwent a successful
mobilization of peripheral blood stem cells (PBSC) using
cyclophosphamide 7 g ⁄m2 plus granulocyte colony-stimu-
lating factor (10 lg ⁄ kg ⁄ d) with a yield of 6Æ5 · 106 ⁄ kg
CD34+. In January 2000, high-dose therapy was adminis-
tered with idarubicin (21 mg ⁄m2, d )9 to d 8 and melph-
alan 140 mg ⁄m2, d )3) followed by reinfusion of the PBSC.
Twelve months after transplant the patient is well and still
in CR.
In conclusion, the case reported here, which showed an
impressive responsiveness to pentostatin, suggests that this
purine nucleoside analogue can obtain a CR with negligible
toxicity. Moreover, pretreatment with pentostatin did not
impair the collection of PBSC with the schedule used in this
patient. To the best of our knowledge this is the first case
treated successfully with pentostatin. We think that it could
be reasonable to consider therapy with pentostatin as a
possible option for induction therapy of patients affected by
HScdTCL.
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EFFICACY OF THALIDOMIDE IN THE TREATMENT OF VAD-REFRACTORY PLASMA CELL
LEUKAEMIA APPEARING AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION
FOR MULTIPLE MYELOMA
Positive results have been reported with thalidomide in
patients with refractory multiple myeloma (MM) (Singhal
et al, 1999). However, the efficacy of this drug in plasma
cell leukaemia (PCL), the most aggressive form of MM, has
not been yet widely evaluated. We report here the signifi-
cant activity of thalidomide in a patient with VAD (vinc-
ristine, doxorubicin, dexamethasone)-refractory PCL,
appearing several months after autologous stem cell trans-
plantation for MM.
This 67-year-old woman presented in January 2000 with
a diagnosis of Durie–Salmon stage III MM. Laboratory
investigations showed anaemia [haemoglobin (Hb)
8Æ7 g ⁄ dl], monoclonal paraprotein (IgG kappa, 40 g ⁄ l),
and normal C-reactive protein, beta2-microglobulin,
calcium and creatinine levels. No Bence–Jones proteinuria
was noted. A bone marrow examination revealed 28%
plasma cells. Radiographs found several femoral and
vertebral osteolytic lesions. She received three courses of
VAD combined with pamidronate infusions. Following this
treatment, the paraprotein concentration fell to 16 g ⁄ l,
the Hb level raised to 10Æ5 g ⁄ dl and only 7% plasma cells
were seen on marrow smears. After an additional VAD
course, the patient was treated with 4 g ⁄m2 cyclophosph-
amide in order to collect peripheral blood stem cells. The
target dose of progenitors was obtained using only two
leukaphereses. After a fifth course of VAD, an autologous
transplant was performed in August 2000 with high-dose
melphalan (200 mg ⁄m2) as the preparative regimen. The
post-transplant medications included clodronate, folic acid
and penicillin. The patient was then considered to be in
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complete response (normal blood counts, near absence of
paraprotein on serum electrophoresis, 1% marrow plasma-
cytosis).
Her follow-up was unremarkable until she complained
of progressively worsening pain in her left arm and was
admitted to our department on July 3 2001. A large
osteolytic lesion of the humerus was evidenced on X-ray.
On the skeletal survey, no progression was evidenced
concerning the other osteolytic lesions. The haemogram
was normal, but an increase in monoclonal paraprotein
(14 g ⁄ l) and bone marrow plasma cells (28%) confirmed
the MM relapse. VAD protocol was introduced again (first
course: July 3 2001) and the patient received local
radiotherapy (45 Gy). However, 4 weeks after VAD initi-
ation, the lactate dehydrogenase level was 1246 IU ⁄ l
(upper normal limit: 618 IU ⁄ l) and the haemogram
showed a hyperleucocytosis 15Æ4 · 109 ⁄ l with 20% circu-
lating plasma cells (3Æ08 · 109 ⁄ l). Bone marrow aspirate
revealed a massive infiltration by 90% plasma cells. A
diagnosis of secondary PCL was made. Considering the
VAD-refractoriness, thalidomide (50 mg capsules, Laphal
laboratory, Allauch, France) was initiated under compas-
sionate use at 200 mg ⁄ d in two divided doses on August
7. On August 17, our patient developed fever > 39C in a
pancytopenic setting: 0Æ9 · 109 ⁄ l leucocytes (16% neu-
trophils, only 1% peripheral myeloma cells), 10Æ9 g ⁄ dl Hb
and 6 · 109 ⁄ l platelets. A coagulase-negative staphylococ-
cus septicaemia was evidenced. This episode resolved
under intravenous antibiotics, transfusions and five injec-
tions of granulocyte colony-stimulating factor. During this
period, the dose of thalidomide was escalated to 300 mg ⁄ d
and dexamethasone 40 mg ⁄ d was added for 4 d. This
latter agent induced a significant and prolonged hypergly-
caemia and its further use was precluded. Four weeks
later, the haemogram was markedly better, with
4Æ3 · 109 ⁄ l leucocytes (78% neutrophils, absence of
plasma cells), Hb 10 g ⁄ dl, 279 · 109 ⁄ l platelets. From
October 2, the administered dose of thalidomide was
increased to 400 mg ⁄ d. At the time of writing, more than
3 months after thalidomide initiation, the patient has
remained symptom-free, in good haematological response
[4Æ7 · 109 ⁄ l leucocytes (73% neutrophils, no circulating
plasma cells), 10Æ7 g ⁄ dl Hb, 172 · 109 ⁄ l platelets, 8%
marrow plasma cells, serum paraprotein level at 11 g ⁄ l].
No significant side-effects were noted.
PCL represents an extremely aggressive entity which can
appear either de novo (primary form) or terminating the
course of MM (secondary form). This disease is characterized
by > 2 · 109 ⁄ l circulating plasma cells. Melphalan-based
treatments are poorly effective (about 2 months median
survival using the Alexanian scheme) (Dimopoulos et al,
1994). Thalidomide has been validated recently for treating
refractory MM (Singhal et al, 1999). Apart from its
anti-angiogenic, immunomodulatory and myeloma cell
pro-apoptotic properties, this agent modulates adhesive
interactions between tumour cells and the bone marrow
microenvironnement (Hideshima et al, 2000). Interestingly,
some adhesion molecules are lost on leukaemic plasma cells,
explaining their escape from the marrow. A direct dose-
dependent effect of thalidomide on MM cells has been
suggested (Hideshima et al, 2000). Furthermore, an in vitro
synergy between this component and dexamethasone has
been demonstrated (Hideshima et al, 2000).
Here, we had to manage an aggressive MM progres-
sion associated with PCL features < 12 months after
autografting. Of note, this evolution occurred following
therapy with the VAD regimen, which is thought to be the
most potent treatment of PCL (Dimopoulos et al, 1994).
However, the efficacy of thalidomide in VAD-resistant MM
cases was clearly demonstrated in the pivotal study (Singhal
et al, 1999). We administered thalidomide in two daily
doses in order to try to improve time to achieve remission,
response rate and tolerance (Juliusson et al, 2000; Blade´
et al, 2001). The response, obtained with only 200 mg ⁄ d
after a brief period of aplasia, was rapid, durable and
subsequently not associated with significant side-effects.
Blade´ et al (2001) have recently pointed out that
thalidomide had no effect in soft-tissue plasmacytomas.
This suggested that the effectiveness of the drug depends on
the tumour location (marrow vs extramedullary sites)
(Blade´ et al, 2001). Thus, thalidomide appears to be an
attractive agent in PCL, the most severe form of plasma cell
disorders, but its best modalities of use (dose, association
with other agents) remain to be determined in larger series.
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RED CELL LIFESPAN ESTIMATION BY 5 1Cr LABELLING
A recent review (Dacie, 2001) prompts me to try and put
the estimation of red cell lifespan by 51Cr labelling into
perspective. In truth, this investigation is now so
infrequently attempted that its technical limitations have
been forgotten and there is a danger that it might be
accepted at face value. While it was undoubtedly an
advance on Ashby’s original attempt, it was never a reliable
way of measuring red cell lifespan.
At a simplistic level the method appears straightforward.
The subjects own red cells are incubated in vitro with a
solution of 51Cr chromium chloride. At intervals after
reinjection the amount of 51Cr remaining in the circulation
is measured and from this an estimation of the red cell
lifespan is calculated.
In truth what is calculated is the half-life of 51Cr in the
circulation. The reason why this does not equate with red
cell lifespan is that 51Cr is lost from the red cells in the
circulation at a rate which is equal to or greater than the rate
at which it is lost as red cells are cleared. Worse still, this rate
of elution is unpredictable. Some studies have attempted to
correct this by using an elution correction factor of 1% per
day – about the same rate as red cells might be expected to be
cleared. This figure was based on a study of 20 patients in
one laboratory a long time ago (Mollinson, 1961). Even then
it showed that the elution rate varied over a twofold range,
that is, in some patients the loss of chromium by this route
could be double the rate of red cell clearance.
When 59Fe kinetic studies were available to assess true
red cell lifespan they showed the inherent unreliability of
the method as a means of assessing red cell lifespan,
although their impracticability did not offer a clinical
alternative (Napier et al, 1979). At the moment, the
reticulocyte percentage is the only practical (but indirect)
assessment of red cell lifespan available. This is not because
it reflects erythropoietic compensation for haemolysis, but
simply because it indicates a change in the proportion of
young to old red cells. Such limited data suggests that when
the reticulocyte percentage exceeds 2Æ5% the red cell
lifespan is likely to be < 30 d.
Notwithstanding this, it is time to remove the 51Cr
assessment of red cell lifespan from haematological practice
and to recognize that any results or interpretation that have
been based on such a fundamentally flawed technique will
have been equally flawed.
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TREATMENT OF PRIMARY CHRONIC COLD AGGLUTININ DISEASE WITH RITUXIMAB:
MAINTENANCE THERAPY MAY IMPROVE THE RESULTS
Berensten et al (2001) recently reported on the efficacy of
rituximab in primary chronic cold agglutinin disease
(CAD). In 4 ⁄6 patients CAD was associated with lymph-
oplasmocytic lymphoma and these patients had favourable
responses. No response was observed in the two remain-
ing patients with no signs of lymphoma. Three responding
patients have been previously reported (Lee & Klueck,
1998; Bauduer, 2001; Layios et al, 2001) and all three
had also low-grade lymphoma-associated CAD, suggesting
that the results may be better for this condition. There-
fore, we agree with the statement of Berensten et al
(2001) that the failure of two patients to respond may
possibly relate to absent or atypical signs of lymphopro-
liferative disease.
We report the case of a patient with refractory CAD not
associated with any sign of lymphoproliferative disease who
poorly responded to induction therapy with rituximab but
who went into complete remission after 6 months of
maintenance therapy.
A 77-year-old Caucasian woman presented in October
1991 for weakness and dyspnoea. There were no enlarged
lymph nodes or hepatosplenomegaly. Haemoglobin was
6Æ9 g ⁄ dl and the reticulocyte count was 222 · 109 ⁄ l. The
lactate dehydrogenase (LDH) level was 929 UI ⁄ l (normal
< 220 UI ⁄ l) and haptoglobin was below the detection limit.
The direct antiglobulin test was positive for polyvalent
serum and complement. Cold agglutinins of the IgM type
showing anti-I specificity were positive with a titre of
1 ⁄2072. No abnormal cell population was detected using
lymphocyte immunophenotyping and the bone marrow
smears were unremarkable. Serum protein electrophoresis
and immunofixation were normal. She had received
prednisolone (1 mg ⁄ kg ⁄ d) from November 1991 until
February 1994 associated with cyclophosphamide
(150 mg ⁄ d) from January 1992 until February 1994, with
complete resolution of signs of haemolysis. She remained in
stable complete remission until January 2001, when acute
relapse occurred.
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Haemoglobin was 6Æ7 g ⁄ dl, LDH was 989 UI ⁄ l and
haptoglobin was below the detection limit. The direct
antiglobulin test was positive for polyvalent serum and
complement. Cold agglutinins were positive with a titre of
> 1 ⁄2400. Treatment with corticosteroids and cyclophosph-
amide was resumed but did not improve the haemolysis and
the patient required multiple transfusions. She then received
four weekly doses of rituximab at 375 mg ⁄m2 each
(Mabthera, Laboratoires Roche, France) from February
2001, with good tolerance. Cyclophosphamide was stopped
and corticosteroids tapered. Red cell transfusions were
stopped after the first rituximab infusion and the haemo-
globin level raised to 10Æ5 g ⁄ dl at the end of March.
Unfortunately, haemolytic signs reappeared (haemoglobin
8Æ8 g ⁄ dl, LDH 940 UI ⁄ l, haptoglobin < 0Æ08 g ⁄ l) in April
2001, 6 weeks after the last rituximab infusion. It was then
decided to resume the treatment with rituximab using
a different schedule: one injection every 2 weeks for
2 months, then progressively tapered to every 3, 4 and,
finally, 6 weeks. A complete remission was achieved in
6 months. Haemoglobin, reticulocytes, LDH and haptoglo-
bin were all within the normal range. At the time of writing
the patient is still doing well in complete remission with one
maintenance injection every 2 months.
CAD is a difficult disease to treat. The preliminary
results observed with rituximab are very promising, but it
seems that the response is less favourable in patients
without associated signs of lymphoproliferative disease.
Our case report highlights, for the first time, that complete
remission can be achieved, even in this particular setting,
using induction therapy with rituximab followed by a
maintenance phase. The use of maintenance therapy
seems promising to further improve the results of ritux-
imab in CAD, although further studies are warranted to
permit any general statement about the value of main-
tenance therapy.
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